You just read:

PROVENGE® (sipuleucel-T) Demonstrates Sustained Immune Response Two Years after Treatment in Biochemically-Recurrent Prostate Cancer

News provided by

Valeant Pharmaceuticals International, Inc.

Feb 25, 2015, 08:00 ET